Roche
NEWS
This week had a few disappointing clinical trials, as do most weeks, but it also had a number of significant successes. Here’s a look at some of the clinical trials that met their primary endpoints this week.
Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.
Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.
A recent survey shows that 90 percent of biopharma companies are making significant investments in real-world evidence capabilities to support multiple annual objectives that include driving drug development and meeting regulatory requirements.
The FDA accepted Genentech’s New Drug Application (NDA) for baloxavir marboxil, a single-dose, oral flu treatment for people 12 years and older. It also granted it Priority Review.
An experimental triple combination treatment for cystic fibrosis has landed Vertex Pharmaceuticals at the top of EvaluatePharma’s “World Preview 2018” list.
The U.S. Food and Drug Administration (FDA) accepted Merck’s new supplemental Biologics License Application (sBLA) for Keytruda.
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
There is another change coming to the senior leadership team at Swiss pharma giant Roche.
JOBS
IN THE PRESS